269 related articles for article (PubMed ID: 36647536)
21. Engineering Escherichia coli Nissle 1917 as a microbial chassis for therapeutic and industrial applications.
Yu M; Hu S; Tang B; Yang H; Sun D
Biotechnol Adv; 2023 Oct; 67():108202. PubMed ID: 37343690
[TBL] [Abstract][Full Text] [Related]
22. Development of probiotic E. coli Nissle 1917 for β-alanine production by using protein and metabolic engineering.
Hu S; Fei M; Fu B; Yu M; Yuan P; Tang B; Yang H; Sun D
Appl Microbiol Biotechnol; 2023 Apr; 107(7-8):2277-2288. PubMed ID: 36929190
[TBL] [Abstract][Full Text] [Related]
23. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Analysis of the Physiological Characterization of Escherichia coli Nissle 1917.
Ramadevi S; Shelin R; Shanmugaraja M
Curr Microbiol; 2023 Mar; 80(5):150. PubMed ID: 36976334
[TBL] [Abstract][Full Text] [Related]
25.
He L; Yang H; Liu F; Chen Y; Tang S; Ji W; Tang J; Liu Z; Sun Y; Hu S; Zhang Y; Liu X; Huang W; Ding X; Xia L
Oncotarget; 2017 Oct; 8(49):85772-85782. PubMed ID: 29156755
[TBL] [Abstract][Full Text] [Related]
26.
Liu Q; Gai Y; Chen Y; Lan X; Jiang D
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452187
[TBL] [Abstract][Full Text] [Related]
27. Nattokinase enhances the preventive effects of Escherichia coli Nissle 1917 on dextran sulfate sodium-induced colitis in mice.
Liang M; Zhang J; Yang Y; Xia Y; Liu L; Liu L; Wang Q; Gao X
World J Microbiol Biotechnol; 2022 Nov; 39(1):8. PubMed ID: 36350434
[TBL] [Abstract][Full Text] [Related]
28. Probiotic Escherichia coli Nissle 1917 propelled micro-robot with pH sensitivity for hypoxia targeted intestinal tumor therapy.
Wang T; Yin Q; Huang HY; Wang Z; Song H; Luo X
Colloids Surf B Biointerfaces; 2023 May; 225():113277. PubMed ID: 36996630
[TBL] [Abstract][Full Text] [Related]
29. Amelioration of cadmium- and mercury-induced liver and kidney damage in rats by genetically engineered probiotic Escherichia coli Nissle 1917 producing pyrroloquinoline quinone with oral supplementation of citric acid.
Raghuvanshi R; Chaudhari A; Kumar GN
Nutrition; 2016; 32(11-12):1285-94. PubMed ID: 27209211
[TBL] [Abstract][Full Text] [Related]
30. Probiotic E. coli Nissle 1917 biofilms on silicone substrates for bacterial interference against pathogen colonization.
Chen Q; Zhu Z; Wang J; Lopez AI; Li S; Kumar A; Yu F; Chen H; Cai C; Zhang L
Acta Biomater; 2017 Mar; 50():353-360. PubMed ID: 28069496
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects resulting from oral administration of
Souza ELS; Campos CLV; Reis DC; Cassali GD; Generoso SV; Cardoso VN; Azevedo V; Medeiros JD; Fernandes GR; Nicoli JR; Martins FS
Benef Microbes; 2020 Dec; 11(8):779-790. PubMed ID: 33191778
[TBL] [Abstract][Full Text] [Related]
32. Pre- and Neonatal Imprinting on Immunological Homeostasis and Epithelial Barrier Integrity by
Sarate PJ; Srutkova D; Geissler N; Schwarzer M; Schabussova I; Inic-Kanada A; Kozakova H; Wiedermann U
Front Immunol; 2020; 11():612775. PubMed ID: 33679699
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of E. coli Nissle 1917 on chickens infected with Salmonella pullorum.
Sun C; Gao X; Sun M; Wang Z; Wang Y; Zhao X; Jia F; Zhang T; Ge C; Zhang X; Zhang M; Yang G; Wang J; Huang H; Shi C; Yang W; Cao X; Wang N; Zeng Y; Wang C; Jiang Y
Microb Pathog; 2022 Nov; 172():105768. PubMed ID: 36096456
[TBL] [Abstract][Full Text] [Related]
34. Escherichia coli Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses.
Vlasova AN; Shao L; Kandasamy S; Fischer DD; Rauf A; Langel SN; Chattha KS; Kumar A; Huang HC; Rajashekara G; Saif LJ
Eur J Immunol; 2016 Oct; 46(10):2426-2437. PubMed ID: 27457183
[TBL] [Abstract][Full Text] [Related]
35. The beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice.
Ma J; Wang J; Xu L; Liu Y; Gu J
Int J Obes (Lond); 2022 May; 46(5):1002-1008. PubMed ID: 35079130
[TBL] [Abstract][Full Text] [Related]
36. Escherichia coli Nissle 1917 secondary metabolism: aryl polyene biosynthesis and phosphopantetheinyl transferase crosstalk.
Jones CV; Jarboe BG; Majer HM; Ma AT; Beld J
Appl Microbiol Biotechnol; 2021 Oct; 105(20):7785-7799. PubMed ID: 34546406
[TBL] [Abstract][Full Text] [Related]
37. K5 Capsule and Lipopolysaccharide Are Important in Resistance to T4 Phage Attack in Probiotic
Soundararajan M; von Bünau R; Oelschlaeger TA
Front Microbiol; 2019; 10():2783. PubMed ID: 31849915
[TBL] [Abstract][Full Text] [Related]
38. The Combined Escherichia coli Nissle 1917 and Tryptophan Treatment Modulates Immune and Metabolome Responses to Human Rotavirus Infection in a Human Infant Fecal Microbiota-Transplanted Malnourished Gnotobiotic Pig Model.
Michael H; Srivastava V; Deblais L; Amimo JO; Chepngeno J; Saif LJ; Rajashekara G; Vlasova AN
mSphere; 2022 Oct; 7(5):e0027022. PubMed ID: 36073800
[TBL] [Abstract][Full Text] [Related]
39. Delivery of E. coli Nissle to the mouse gut by mucoadhesive microcontainers does not improve its competitive ability against strains linked to ulcerative colitis.
Bondegaard PW; Torp AM; Guerra P; Kristensen KA; Christfort JF; Krogfelt KA; Nielsen LH; Zor K; Boisen A; Mortensen MS; Bahl MI; Licht TR
FEMS Microbiol Lett; 2023 Jan; 370():. PubMed ID: 37863838
[TBL] [Abstract][Full Text] [Related]
40. Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.
Kleta S; Nordhoff M; Tedin K; Wieler LH; Kolenda R; Oswald S; Oelschlaeger TA; Bleiss W; Schierack P
Infect Immun; 2014 May; 82(5):1801-12. PubMed ID: 24549324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
